Over 94K New Cases Take India’s COVID-19 Tally Past 47 Lakh

Google Search for Web:

Kajal Agrawal

Error validating access token: Session has expired on Sunday, 31-Mar-24 00:00:14 PDT. The current time is Monday, 25-Nov-24 00:05:40 PST.

Over 94K New Cases Take India’s COVID-19 Tally Past 47 Lakh ^Featured

Super User 13 सितम्बर 2020

Rate this item

(0 votes)

font size decrease font size increase font size
Print
Email

India on Sunday, 13 September, reported 94,371 new cases of coronavirus, taking the tally in the country to 47,54,356, including 9,73,175 active cases. The death toll increased by 1,114 to 78,586.

Clinical trials in Britain have resumed for the Astrazeneca and Oxford University COVID-19 vaccine after the Medicines Health Regulatory Authority (MHRA) certified that it was safe to do so, reported Reuters.

Union Home Minister Amit Shah was admitted to Delhi’s AIIMS on Saturday night, just two weeks after he was discharged from the hospital
Union AYUSH Minister Shripad Naik was discharged from a hospital in Panaji on Saturday after being admitted for COVID-19 for a month
With the Delhi Metro resuming services on its Airport Express Line on Saturday, all its lines are now operational
Globally, over 28.3 million cases of coronavirus have been recorded so far, with India being the second worst-affected country

India's Total Case Tally Crosses 47 Lakh Mark

India on Sunday, 13 September, reported 94,371 new cases of coronavirus, taking the tally in the country to 47,54,356, including 9,73,175 active cases. The death toll increased by 1,114 to 78,586.

India’s COVID-19 Recoveries Rise Exponentially: Health Ministry

India’s Ministry of Health has said that India's COVID-19 recoveries have witnessed a steep exponential rise - from 50,000 in May to over 36 lakhs in September. A high level of more than 70,000 recoveries are reported every day and recoveries are nearly 3.8 times the active cases, the Health Ministry added.

AstraZeneca Resumes Oxford COVID Vaccine Trial

The late stage trials of the vaccine, which is at one of the most advanced stages of development compared to other vaccines in the world, was stopped last week after a study subject in Britain developed an illness.